Filtered By:
Specialty: International Medicine & Public Health
Drug: Warfarin
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 58 results found since Jan 2013.
Perceived Advantages and Disadvantages of Oral Anticoagulants, and the Trade-offs Patients Make in Choosing Anticoagulant Therapy and Adhering to Their Drug Regimen
Oral anticoagulant therapy (OAT) is proven to be highly effective for stroke prevention in patients suffering from atrial fibrillation (AF) [1,2]. Vitamin K antagonists (VKAs), particularly warfarin, which is the most commonly used VKA, have long been the standard of care to prevent AF-related stroke [3]. However, in recent years the European Medicines Agency has approved a number of direct oral anticoagulants (DOACs) as (possible) alternatives to VKAs. The perceived benefits of DOACs include their high efficacy and low risk of bleeding, the rapid onset/offset of action, fewer food and drug interactions, and predictable ph...
Source: Patient Education and Counseling - July 2, 2018 Category: International Medicine & Public Health Authors: Melissa C.W. Vaanholt, Marieke G.M. Weernink, Clemens von Birgelen, Catharina G.M. Groothuis-Oudshoorn, Maarten J. Ijzerman, Janine A. van Til Source Type: research
Apixaban is a safe alternative to warfarin during catheter ablation of atrial fibrillation
(European Society of Cardiology) Apixaban and warfarin are equally safe during catheter ablation of atrial fibrillation, according to results of the AXAFA-AFNET 5 trial presented today in a late-breaking trial session at EHRA 2018, a European Society of Cardiology (ESC) congress.1 There were similar rates of stroke and bleeding, and an improvement in cognitive function was shown for the first time.
Source: EurekAlert! - Medicine and Health - March 20, 2018 Category: International Medicine & Public Health Source Type: news
Cost-Effectiveness of Apixaban For Stroke Prevention In Atrial Fibrillation: An Kazakhstan Perspective
The objective of this study was to evaluate the cost-effectiveness of apixaban against other NOACs and warfarin from the considering costs and savings for public payers perspective in Kazakhstan
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: A Kostyuk, A Almadiyeva, T Nurgozhin Source Type: research
Cost-Effectiveness of Edoxaban In Patients With Non-Valvular Atrial Fibrillation In Hong Kong
Atrial fibrillation (AF) is a common arrhythmia associated with debilitating consequences such as stroke, heart failure and venous thromboembolism. In HK, 20-25% of stroke cases are related to AF leading to a significant burden. Warfarin has been the frontline oral anticoagulant for AF but with high bleeding risk and hence monitoring and dose adjustment are required. The non-vitamin-K antagonist oral anticoagulants (NOACs) are alternatives to warfarin for preventing stroke and systemic embolism in non-valvular AF (NVAF) patients.
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: DB Wu, WY Choon, KK Lee Source Type: research
Health Care Cost In Patients Undergoing Electrical Cardioversion: An Analysis From The Edoxaban Versus Warfarin In Subjects Undergoing Cardioversion of Atrial Fibrillation (ENSURE-AF) Study
Electrical cardioversion (EC) restores and maintains sinus rhythm in atrial fibrillation (AF) patients. Edoxaban, a direct oral anticoagulant indicated for prevention of stroke or systemic embolic event (SEE) in patients with non-valvular atrial fibrillation (NVAF) was compared with enoxaparin –warfarin in patients undergoing EC in ENSURE-AF (NCT 02072434) study, a phase 3b open-label, multi-national open-label trial comparing edoxaban with enoxaparin/warfarin followed by warfarin alone in 2,199 NVAF patients.
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: J Rodriguez Barrrios, A Goette, J Kwong, MD Ezekowitz, M Banach, SP Hjortsh øj, D Zamoryakhin, G Lip Source Type: research
Apixaban lowers stroke risk in AF patients undergoing cardioversion (EMANATE)
(European Society of Cardiology) Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-na ï ve patients with atrial fibrillation scheduled for elective cardioversion, according to late-breaking results from the EMANATE trial presented today in a Hot Line LBCT Session at ESC Congress. Rates of bleeding were similar between the two groups.
Source: EurekAlert! - Medicine and Health - August 28, 2017 Category: International Medicine & Public Health Source Type: news
Healthcare utilization and costs for patients initiating Dabigatran or Warfarin
Novel oral anticoagulants (NOAC) such as dabigatran, when compared to warfarin, have been shown to potentially reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) together with l...
Source: Health and Quality of Life Outcomes - June 21, 2017 Category: International Medicine & Public Health Authors: Shannon L. Reynolds, Sameer R. Ghate, Richard Sheer, Pranav K. Gandhi, Chad Moretz, Cheng Wang, Stephen Sander, Mary E. Costantino, Srinivas Annavarapu and George Andrews Source Type: research
Dabigatran superior to warfarin when anticoagulation is resumed after bleeding
(University of Pittsburgh Schools of the Health Sciences) In the first analysis of how to treat patients on anticoagulants who suffer a major bleeding event, a clinical practice that routinely gives doctors pause, while also evaluating a new drug, University of Pittsburgh researchers aim to provide much-needed guidance to clinicians trying to balance the risks of stroke versus bleeding when determining the best treatment.
Source: EurekAlert! - Social and Behavioral Science - December 1, 2016 Category: Global & Universal Source Type: news
How safe and effective are new drugs for stroke prevention?
(Mayo Clinic) For decades, warfarin was the only oral blood thinner available to reduce the risk of stroke for patients with atrial fibrillation. Warfarin use is cumbersome, because it requires ongoing blood test to monitor the effect and has numerous drug and food interaction. Now a number of non-vitamin K antagonist oral anticoagulant drugs are available for patients with atrial fibrillation and claim to revolutionize the care for patients with atrial fibrillation.
Source: EurekAlert! - Medicine and Health - October 3, 2016 Category: Global & Universal Source Type: news
New oral anticoagulants provide same stroke prevention as warfarin but cause less bleeding
(European Society of Cardiology) The new oral anticoagulants provide the same stroke prevention as warfarin but cause less intracranial bleeding, reports an observational study in more than 43,000 patients presented at ESC Congress 2016 today by Dr. Laila Staerk, a research fellow at Herlev and Gentofte University Hospital, Denmark.
Source: EurekAlert! - Medicine and Health - August 27, 2016 Category: Global & Universal Source Type: news
PM176 Effect of Mitral Regurgitation in Non-Rheumatic Atrial Fibrillation Patients Taking and not Taking Warfarin on Stroke and Bleeding
Atrial fibrillation (AF) increases risk of stroke significantly. Prevention of this complication by using anticoagulant is recommended when the benefits outweigh the risks. Many AF patients also have mitral regurgitation (MR) as co-morbidity. However, there is lack of data describing the relationship between the bleeding risk and expected benefit from using anticoagulant in this kind of patients.
Source: CVD Prevention and Control - May 31, 2016 Category: Global & Universal Authors: Y. Vorasettakarnkij, K. Chintanavilas Tags: Poster Abstract Source Type: research
Cost Effectiveness of Apixaban (Novel Oral Anti-Coagulant) Compared with Conventional Therapy for Stroke Prophylaxis among Renal Impaired Patients with Atrial-Fibrillation from Perspective of Us Third Party Payer
Atrial Fibrillation (AF) has been a major risk factor for the development of stroke making anticoagulation therapy necessary. While on prophylaxis treatment, renal impaired patients on conventional anticoagulation (Warfarin) are at an increased risk for major bleeding. Apixaban has been shown to have better safety profile than Warfarin in face to face clinical trial. However, no study were found to have compared the cost effectiveness of Apixaban with Warfarin among renal impaired patients. We attempted to estimate the short term (one year) cost effectiveness of Apixaban compared to Warfarin for stroke prophylaxis among re...
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: A Kumar, W Wu, M Nili Source Type: research
Trends in the Utilization of Warfarin and Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation
Warfarin has been used for more than 60 years to decrease the risk of stroke and death in patients with atrial fibrillation (AF). In recent years, the FDA has approved four non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in AF: dabigatran, rivaroxaban, apixaban, and edoxaban.
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: A Alalwan, S Voils, A Hartzema Source Type: research
Patterns and Predictors of Discontinuation and Switch in Atrial Fibrillation Patients Treated with Non-Vitamin K Antagonist Oral Anticoagulants
Recent clinical trials have established non-vitamin K antagonist oral anticoagulants (NOACs) as viable alternatives to warfarin in stroke prevention for atrial fibrillation. A major challenge in routine clinical practice is the high rate of medication discontinuation and switching. There are currently few large studies offering estimates of drug persistence with NOACs. Moreover, little is known about what drives patients’ choice and behavior regarding patterns of long-term medication use. Using a large heterogeneous cohort of patients, we aimed to investigate the patterns and predictors of switch and discontinuation amon...
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: X Yao, ND Shah, LR Sangaralingham, BJ Gersh, PA Noseworthy Tags: CARDIOVASCULAR DISORDERS – Patient-Reported Outcomes & Patient Preference Studies Source Type: research
The Uptake of Non-Vitamin K Oral Anticoagulants in Ireland: Balancing Cost-Effectiveness Analysis and Budget Impact
For many years vitamin K antagonists (usually warfarin) were the only oral anticoagulants available to reduce stroke risk in Atrial fibrillation (AF). The non-vitamin K oral anticoagulants (NOACs) were first licensed in Ireland for stroke prevention in non-valvular AF with the approval of dabigatran etexilate in 2011. Rivaroxaban followed later that year, apixaban in 2013 and edoxaban in 2015. The National Centre for Pharmacoeconomics (NCPE) reviewed all the NOACs for cost-effectiveness prior to reimbursement approval in Ireland.
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: M Barry, S Clarke, N Geraghty Source Type: research
